Gilead Partners with Assembly Biosciences in $84.8 Million Collaboration for Antiviral Therapies
Gilead Sciences (NASDAQ: GILD) has announced a significant 12-year collaboration with antiviral specialist Assembly Biosciences...
Gilead Sciences (NASDAQ: GILD) has announced a significant 12-year collaboration with antiviral specialist Assembly Biosciences...